EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring

Shivani Garg iD, Benoît Blanchet, Yann Nguyen iD, Fauzia Hollnagel, Ada Clarke, Michelle Petri iD, Murray B Urowitz iD, John G Hanly iD, Caroline Gordon iD, Sang-Cheol Bae iD, Juanita Romero-Diaz, Jorge Sanchez-Guerrero und 31 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Shivani Garg und 42 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin School of Medicine and Public Health, Madison. Hauptthemen laut MEDLINE: Hydroxychloroquine, Lupus Erythematosus, Systemic, Drug Monitoring, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, Rheumatology Research Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.

Methods

This observational study included patients (N = 2,010) across the Systemic Lupus International Collaborating Clinics, Wisconsin, international, and French studies who underwent HCQ blood level measurements. Using adjusted spline and logistic regression analyses on the cross‐sectional data, we first identified an HCQ blood level associated with higher HCQ toxicity. Next, we tested if this upper threshold level was supratherapeutic (no further risk reduction for the Systemic Lupus Erythematosus Disease Activity Index 2000 [score ≥6]). Finally, we examined associations between chronic kidney disease (CKD) stage and supratherapeutic (toxic) HCQ blood levels.

Results

Among 1,842 patients (excluding 168 patients with very low HCQ blood levels), 4.9% had HCQ‐related toxicity. Odds of toxicity were 2.1‐fold higher with blood levels ≥1,150 ng/mL and 1.7‐fold higher with the cumulative HCQ dose per 1,000‐g increase. Blood levels ≥1,150 ng/mL were associated with a saturation in therapeutic effect, indicating supratherapeutic levels. Patients with CKD stage ≥3 had 2.3‐fold higher odds of having supratherapeutic levels (≥1,150 ng/mL).

Conclusion

The therapeutic reference range for HCQ blood level monitoring is 750 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineLupus Erythematosus, SystemicDrug MonitoringAntirheumatic AgentsHumansFemaleMaleAdultMiddle AgedCross-Sectional StudiesRenal Insufficiency, ChronicSeverity of Illness IndexReference ValuesLogistic Models

Substanzen

HydroxychloroquineAntirheumatic Agents

Autor:innen und Institutionen

  • University of Wisconsin School of Medicine and Public Health, Madison.
  • Yale University, New Haven, Connecticut.
  • Biologie du Médicament-Toxicologie, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP Centre and Université de Paris, CNRS, INSERM, CiTCoM, U1268, Paris, France.
  • National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP-HP Centre and Université Paris Cité and Centre de Recherche en Epidémiologie et Statistiques, Unité Inserm 1153, Université de Paris…
  • Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Division of Rheumatology, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Shivani Garg, Yann Nguyen, Michelle Petri, Murray B Urowitz, John G Hanly, Caroline Gordon, Sang-Cheol Bae, Sasha Bernatsky, David A Isenberg, Anisur Rahman, Dafna D Gladman, Rosalind Ramsey-Goldman, Graciela S Alarcón, S Sam Lim, Anca Askanase, Alicja Puszkiel

Förderung

  • NIAMS NIH HHS
  • Rheumatology Research Foundation
  • NIH HHS
  • Lupus Foundation of America
  • National Institutes of Health

Zitieren

APA

Garg, S., Blanchet, B., Nguyen, Y., Hollnagel, F., Clarke, A., Petri, M., Urowitz, M. B., Hanly, J. G., Gordon, C., Bae, S. C., Romero-Diaz, J., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., …, & Costedoat-Chalumeau, N. (2026). Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring. Arthritis & Rheumatology. https://doi.org/10.1002/art.70010

Vancouver

Garg S, Blanchet B, Nguyen Y, Hollnagel F, Clarke A, Petri M, et al. Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring. Arthritis & Rheumatology. 2026. doi:10.1002/art.70010

BibTeX
@article{Garg2026,
  author = {Garg, Shivani and Blanchet, Benoît and Nguyen, Yann and Hollnagel, Fauzia and Clarke, Ada and Petri, Michelle and Urowitz, Murray B and Hanly, John G and Gordon, Caroline and Bae, Sang-Cheol and Romero-Diaz, Juanita and Sanchez-Guerrero, Jorge and Clarke, Ann E and Bernatsky, Sasha and Wallace, Daniel J and Isenberg, David A and Rahman, Anisur and Merrill, Joan T and Fortin, Paul R and Gladman, Dafna D and Bruce, Ian N and Ginzler, Ellen M and Dooley, Mary Anne and Ramsey-Goldman, Rosalind and Manzi, Susan and Jönsen, Andreas and Alarcón, Graciela S and Van Vollenhoven, Ronald F and Aranow, Cynthia and Le Guern, Véronique and Mackay, Meggan and Ruiz-Irastorza, Guillermo and Lim, S Sam and Inanc, Murat and Kalunian, Kenneth C and Jacobsen, Søren and Peschken, Christine A and Kamen, Diane L and Askanase, Anca and Buyon, Jill and Chezel, Julie and Puszkiel, Alicja and Costedoat-Chalumeau, Nathalie},
  title = {Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70010}
}
Kostenlos starten →